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(20%). Quality of life, documented with a generic (EQ-
5D) and a disease-specific questionnaire (IBSQOL), showed
that patients are severely affected by IBS. The EQ-5D tar-
iff was decreased to 0.63. The IBSQOL showed that peo-
ple have strong discomfort in daily activities, and mood
and food intake are affected. CONCLUSION: It is obvi-
ous that a reduction in severity of disease will reduce so-
cietal as well as social sickness fund costs. In further re-
search, we will use data to model estimated cost savings
obtained through the introduction of new therapeutic op-
tions with increased effectiveness.
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OBJECTIVE: Patient-reported symptom severity mea-
sures are important for evaluating the effectiveness of
treatments for gastrointestinal diseases because they are
the only measures in clinical evaluation that directly re-
flect the patient experience. Gastroparesis refers to ab-
normal gastric emptying, encompassing a variety of up-
per gastrointestinal symptoms that are difficult to quantify.
The purpose of this study is to describe the development
and initial testing of a new self-report measure, the Pa-
tient Assessment of Upper GastroIntestinal Disorders-
Symptom Severity Index (PAGI-SYM) in subjects with
gastroparesis. METHODS & RESULTS: Instrument
content was based on a review of the published literature
and patient and clinician interviews. The 37-item PAGI-
SYM is comprised of six subscales: heartburn, reflux/re-
gurgitation, nausea/vomiting, abdominal pain, bloating/
early satiety, and other symptoms. Psychometric evalua-
tion of the PAGI-SYM in 120 subjects with gastroparesis
identified through six clinical sites in the US is currently
being completed. Subjects complete the PAGI-SYM, the
SF-36, and a measure of patient-rated change in gastro-
paresis-related symptoms, the Overall Treatment Effect
Scale (OTE), by way of telephone interview. Two-week
reproducibility will be evaluated in 30 subjects. The
PAGI-SYM will be analyzed for internal consistency reli-
ability, reproducibility, and validity. 104 subjects have
been enrolled in the study to date. Data collection is pro-
ceeding with data analysis to be completed by October 1.
CONCLUSION: The results of this study will provide
valuable information on the psychometric properties of
the PAGI-SYM. 
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OBJECTIVES: In recent clinical trials, esomeprazole, a
new proton pump inhibitor, has been shown to be effec-
tive for long-term on demand treatment (medication taken
as needed) to control recurrent symptoms in patients
with Gastro-Oesophageal Reflux Disease (GORD) with-
out oesophagitis. The objective of this analysis was to
evaluate the cost-effectiveness of on demand treatment
with esomeprazole, 20 mg, compared with intermittent
treatment courses with omeprazole, 20 mg, od, or contin-
uous omeprazole treatment following relapse in patients
with GORD without oesophagitis. METHODS: A simple
Markov model was designed to compare the cost-effec-
tiveness of esomeprazole on demand treatment for six
months with a strategy comprising intermittent treatment
courses of omeprazole. In a further comparison, the strict
intermittent omeprazole strategy was replaced by a strat-
egy where continuous treatment was prescribed follow-
ing a first relapse, which better reflects conventional care.
Patient management was based on results from a UK
physician survey of patient management in clinical prac-
tice. The UK survey results were adjusted for Finland and
Sweden based on expert opinions. Direct medical costs in
Finland, Sweden and the UK were used. Time with
GORD, defined as weeks with symptoms during relapses,
was used as the measure of effectiveness. RESULTS: Time
with GORD was 0.4 weeks per patient in the esomepra-
zole on demand strategy, 2.2 weeks in the intermittent
omeprazole strategy and 1.8 weeks in the conventional
omeprazole strategy. The esomeprazole strategy incurred
lower costs than either omeprazole strategy. This analysis
represents a conservative estimate of the cost-effective-
ness of on demand treatment with esomeprazole, since
data from clinical trials using placebo plus antacids as
rescue medication were used as a substitute for relapse in
patients with GORD without oesophagitis.
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OBJECTIVES: Patients with Gastro-Oesophageal Reflux
Disease (GORD) in primary care usually receive empiri-
cal treatment based on symptoms, without referral for
endoscopy. Esomeprazole is a new proton pump inhibi-
